Head and Neck cancer patients receiving radiation therapy (with or without chemotherapy) suffer several oral complications, such as oral mucositis, which impairs quality of life of patients during radiotherapy and in the post-treatment follow-up period. The use of topical agents to protect oral mucosa against radiation-induced toxicity is part of the routine clinical practice. Among these products, the use of mouthwashes and/or gels are extensively used in the Centro Oncológico Clara Campal - Hospital HM Sanchinarro. Once such product is a proprietary formulation based on natural ingredients such as olive oil, betaine, and xylitol (Mucosa Innovations S.L.).
Adults (≥18 years) diagnosed with head and neck cancer
Treated with radiotherapy or chemoradiotherapy, with or without surgery and/or immunotherapy, according to tumor type and stage, between 2019 and 2023
With available medical records documenting clinical assessments of oral mucositis during at least the radiotherapy/CRT treatment period, and that had used the oral mucosa topical measures
Patients with missing or insufficient clinical records required for the study
Patients with concomitant malignancies undergoing active treatment at the same time.
Mucosa Innovations, S.L.
Lead sponsor
Hospital Universitario HM Sanchinarro - Centro Integral Oncológico Clara Campal
Collaborator
Clínica Vilaboa
Collaborator